Huntleigh Healthcare Reports the US FDA’s 510(k) Clearance of Dawes-Redman CTG Analysis to Improve Non-Stress Test Interpretation in Fetuses
Shots:
- The US FDA has granted 510(k) clearance to the Dawes-Redman CTG analysis, improving non-stress test (NST) interpretation in fetuses to help prevent poor outcomes for babies & families
- Dawes-Redman CTG assesses NST traces against criteria of normality, using database of 100,000+ traces & their outcomes, by evaluating basal heart rate, sinusoidal rhythms, & short-term variation (STV) of the fetal heart rate, which cannot be calculated manually
- CTG Analysis was further enhanced by Oxford researchers, reducing trace analysis time from >30min. to 10min. for clinicians; Dawes-Redman CTG is available in Huntleigh’s Sonicaid TEAM3 series & the OBIX BeCA fetal monitor
Ref: Huntleigh | Image: Huntleigh
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
